Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Heberpenta-L
- Development stage
- Unknown
- Lead developer
- Center for Genetic Engineering and Biotechnology
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Heberpenta-L is a liquid pentavalent vaccine developed by the Center for Genetic Engineering and Biotechnology (CIGB) in Cuba. It is indicated for the active immunization of infants and children against diphtheria, tetanus, pertussis (whooping cough), hepatitis B, and invasive diseases caused by *Haemophilus influenzae* type b (Hib). The vaccine is a combination of diphtheria and tetanus toxoids, inactivated whole-cell *Bordetella pertussis*, recombinant hepatitis B surface antigen (HBsAg), and conjugated Hib capsular polysaccharide (PRP). As a fully liquid formulation, it eliminates the need for reconstitution at the point of care, simplifying administration and reducing the risk of contamination. It is typically administered via intramuscular injection and is approved for use in Cuba and other regions where CIGB products are distributed.
- Brand names
- Heberpenta-L
- Other names
- Heberpenta
02
Targets
BCR (Immunoglobulin G B Cell Receptor)
Beyond the preview
Go deeper on Heberpenta-L.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Heberpenta-L.